Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title Sort descending | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | PAR-22-105 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration,… More | ||
| Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | PAR-22-106 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration,… More | ||
| Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) | PAR-22-109 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration,… More | ||
| Diversity Centers for Genome Research (U54 Clinical Trials Optional) | RFA-HG-22-026 | NHGRI | The Diversity Center for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2, section III of the FOA. The MSIs must… More | ||
| Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional) | RFA-HG-22-027 | NHGRI | Funding Opportunity PurposeThe full-scale Diversity Centers for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2… More | ||
| Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed) | PAR-22-031 | NIMH | Reissue of PAR-19-147 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH… More |
||
| Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed) | PAR-22-032 | NIMH | Reissue of PAR-19-146 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH… More |
||
| Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) | PAR-23-081 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-… More | ||
| Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed) | PAR-23-215 | ORIP | The purpose of this funding opportunity announcement (FOA) is to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators (ESIs) who are within 10 years of their… More | ||
| Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) | PAR-21-136 | NIMH | This is a reissue of RFA-MH-18-703: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required). NIMH requires an… More |